Apatinib in the Treatment of Recurrent Atypical/Malignant Meningioma in Adults
Status:
Recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
Apatinib mesylate may be an effective treatment for recurrent atypical/malignant meningioma.
This prospective clinical study is now planned to verify the effectiveness and safety of
apatinib mesylate in the treatment of relapsed atypical/malignant meningioma.